Beta Bionics, Inc. Common Stock
BBNXBeta Bionics, Inc. is a medical device company focused on developing innovative insulin delivery solutions for people with diabetes. It is known for its flagship product, the iLet Bionic Pancreas, an artificial pancreas system designed to automate insulin and glucagon delivery, aiming to improve glucose management and quality of life for users. The company emphasizes blending advanced technology with patient-centered design to address the needs of individuals requiring tight glucose control.
Company News
Scott+Scott is investigating whether Beta Bionics issued misleading statements or failed to disclose material information to investors. The company reported 5,581 new patient starts for Q4 2025, falling short of the 6,078 consensus expectation, causing the stock to plunge 37% to $20.14 on January 9, 2026.
The DJS Law Group is investigating Beta Bionics (NASDAQ: BBNX) for potential securities law violations, alleging the company issued misleading statements or failed to disclose material information. The investigation was triggered after Beta Bionics announced lower-than-expected patient starts for Q4 on January 8, 2026, causing the stock to plumme...
The Schall Law Firm is investigating Beta Bionics, Inc. for potential securities law violations, alleging the company issued false or misleading statements regarding patient starts. Beta Bionics disclosed lower-than-expected patient numbers on January 8, 2026, causing its stock to plummet over 37% the following day. The firm is seeking shareholde...
The Law Offices of Frank R. Cruz announced an investigation into Beta Bionics, Inc. for possible federal securities law violations. The investigation was triggered after Beta Bionics reported preliminary Q4 2025 results showing new patient starts growth of 36% year-over-year, down significantly from 68% in the prior quarter. The stock fell 37% ($...
The DJS Law Group is investigating Beta Bionics (NASDAQ: BBNX) for potential securities law violations, alleging the company issued misleading statements or failed to disclose material information. The investigation was triggered after Beta Bionics announced lower-than-expected patient starts for Q4 2025, causing the stock to plummet 37% on Janua...
